Table 1

Changes in Viability, Myocardial Fiber Architecture, and Cardiac Function

CDCEXOPlacebo
SS
 Pre (%)17 (3)19 (2)
 Post (%)13 (2)18 (3)
 Δ (%)−27 (9)−4 (13)
|HAT|
 Pre (°/%TD)1.00 (0.06)1.02 (0.07)
 Post (°/%TD)1.02 (0.06)0.91 (0.09)
 Δ (%)−2 (5)−14 (4)
LVEF
 Pre (%)41 (3)40 (6)
 Post (%)42 (5)35 (8)
 Δ (%)−2 (7)−17 (6)
LVEDV
 Pre (ml)76 (12)77 (16)
 Post (ml)84 (7)93 (18)
 Δ (%)16 (10)21 (10)
LVESV
 Pre (ml)45 (14)46 (18)
 Post (ml)49 (4)63 (23)
 Δ (%)16 (14)32 (15)
SV
 Pre (ml)29 (2)31 (2)
 Post (ml)34 (3)32 (6)
 Δ (%)9 (5)3 (5)

Values are median (interquartile range).

Δ = normalized change (post – pre)/pre; CDCEXO = exosomes of cardiosphere-derived cells; |HAT| = absolute helix angle transmurality; IQR = interquartile range; LVEDV = left ventricular end-diastolic volume; LVEF = left ventricular ejection fraction; LVESV = left ventricular end-systolic volume; post = post-treatment; pre = pre-treatment; SS = scar size; SV = stroke volume; TD = transmural depth.

  • CDCEXO vs placebo, p < 0.05.

  • pre vs post, p < 0.05. Significant (p = 0.03) reduction in scar size with preserved ejection fraction and helix angle transmurality were observed in the CDCEXO group. Significant (p = 0.03 and p = 0.03, respectively) reduction in EF and helix angle transmurality with no change in scar size were observed in the placebo group.